Opiant Pharmaceuticals Overview

Opiant Pharmaceuticals Research & Development

Research & Development expenses for OPNT.

Quarterly R&D Expenses

$4.13M

↓ 15.31% YoY

As of Sep 30, 2022

Annual R&D Expenses (TTM)

$25.59M

↑ 54.18% YoY

Trailing 12 months ending Sep 30, 2022

Average R&D Expenses (Comparison Companies)

Research & Development History

Research & Development Comparison

Annual Research & Development Growth Rate (%)

Annual Research & Development Growth (Absolute)

Jump to metric

Total Revenue Cost of Revenue Gross Profit Research & Development Selling, General & Admin Operating Income Other Income Expense Net EBIT Income Tax Net Income Profit Margin